The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of alopecia areata: An Australian expert consensus statement
Abstract
Alopecia areata (AA) severity varies from a single small patch to complete loss of scalp hair, body hair, eyelashes and eyebrows. While 40% of all affected individuals only ever get one patch and will achieve a spontaneous complete durable remission within 6 months, 27% will develop additional patches but still achieve complete durable remission within 12 months and 33% will develop chronic AA. Without systemic treatment, 55% of individuals with chronic AA will have persistent multifocal relapsing and remitting disease, 30% will ultimately develop alopecia totalis and 15% will develop alopecia universalis. The unpredictable course and psychological distress attributable to AA contributes to the illness associated with AA. Numerous topical, intralesional and systemic agents are currently used to treat AA; however, there is a paucity of data evaluating their use, effectiveness and tolerability. Topical therapy, including topical glucocorticosteroids, minoxidil and immunotherapy, can be used in cases of limited disease. There are no universally agreed indications for initiating systemic treatment for AA. Possible indications for systemic treatment include rapid hair loss, extensive disease (≥50% hair loss), chronic disease, severe distress or a combination of these factors. Currently available systemic treatments include glucocorticosteroids, methotrexate, ciclosporin, azathioprine, dapsone, mycophenolate mofetil, tacrolimus and sulfasalazine. The optimal treatment algorithm has not yet been described. The purpose of this consensus statement is to outline a treatment algorithm for AA, including the indications for systemic treatment, appropriate choice of systemic treatment, satisfactory outcome measures and when to discontinue successful or unsuccessful treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghanizadeh, A. (2008) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.03743.x · Cited by 70 · cited 1×
“Children and adolescents with AA experience high rates of depression and anxiety disorders.(11) Parents of children affected by AA may also experience anxiety and mood disturbance.”
Background
Cited by
Two Phase 3 Trials of Baricitinib for Alopecia Areata
King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110343 · Cited by 506
Self-citationAlopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
Visible light. Part II: Photoprotection against visible and ultraviolet light
Geisler, A. N., Austin, E., Nguyen, J., Hamzavi, I., Jagdeo, J., & Lim, H. W. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.074 · Cited by 118
Metadata
- Authors
- Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., Sharma, P., Green, J., Eisman, S., Yip, L., Jones, L., & Sinclair, R.
- Venue
- Australasian Journal of Dermatology
- Publisher
- Wiley
- Published
- 2018-11-08
- Volume
- 60
- Issue
- 2
- Pages
- 163-170
- ISSN
- 0004-8380 (ISSN-L)
- 1440-0960
- OpenAlex
- W2900292386
- Cited by
- 181
- References
- 1
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of alopecia areata: An Australian expert consensus statement. https://app.cochat.ai/papers/10.1111/ajd.12941
- The paper
- Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., Sharma, P., Green, J., Eisman, S., Yip, L., Jones, L., & Sinclair, R. (2019). Treatment of alopecia areata: An Australian expert consensus statement. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.12941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.